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SurvivalPulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) due to systemic to
pulmonary shunting is associated with a high risk of morbidity and mortality. In this study we evaluated
4 years treatment effect of bosentan on exercise capacity and quality of life and survival rates in 64 adult
patients with PAH associated with CHD, including patients with Down syndrome (DS). All patients were
evaluated at baseline and during follow-up with laboratory tests, 6-minute walk test, quality of life
questionnaires, and Doppler echocardiography. In total, 13 patients (20%) died during 4-years of follow-up; 4
patients with DS and 9 patients without DS. Mean follow-up of all patients treated with bosentan was 3.5±
1.2 year. We analyzed treatment efﬁcacy separately within patients without DS (n=34) and patients with DS
(n=30). Mean 6-minute walking distance (6MWD) in patients without DS signiﬁcantly increased at
6 months from 417±108 to 458±104 m (+41 m; p=0.002) and signiﬁcant improvement continued to
exist during at least 2.5 years of follow-up (p=0.003). Moreover, stroke volume increased signiﬁcantly
(p=0.02). In the patients with DS, 6-MWD, stroke volume and quality of life remained stable during
treatment. In this study we demonstrate a prolonged beneﬁcial effect of bosentan treatment on exercise
capacity, stroke volume and quality of life in patients without DS. However the mortality rate of 20% of
patients after 4 years of follow-up remains high.gy, Academic Medical Centre,
el.: +31 20 5662193; fax: +31
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Pulmonary arterial hypertension (PAH) is a rare syndrome of
dyspnoea, fatigue, chest pain and syncope caused by a progressive
increase in pulmonary vascular resistance and deﬁned by a sustained
elevation of pulmonary arterial pressure to more than 25 mm Hg at
rest and a capillary wedge pressure of 15 mm Hg or less [1]. It is
clinically characterised by decreased functional capacity, right ven-
tricular failure and a shortened life expectancy [2,3]. PAH due to
congenital heart disease (CHD) with systemic to pulmonary shunt is a
major subgroup of patients with PAH [4]. CHD–PAH is a result of
systemic to pulmonary shunting and chronic increased ﬂow thatultimately results in adaptations of pulmonary vasculature and
endothelial dysfunction. The advanced stage is called Eisenmenger
syndromewhich forms a small percentage (1%) of all CHD patients [5].
Until recently, treatment options for patients with pulmonary arterial
hypertension were limited. A major breakthrough in the treatment of
patients with PAH has been the introduction of the oral endothelin
receptor antagonist bosentan. Short-term treatment with bosentan
has shown to improvemorbidity of patients with PAH, including those
with Eisenmenger syndrome [6]. However, results on longer-term
treatment response are equivocal and data on quality of life is limited
despite the importance of quality of life assessment [7,8]. Although
several studies reported a persistent beneﬁcial effect of bosentan on
exercise capacity [9–13], other studies reported a gradual decline of
exercise capacity to baseline values after 2 years of bosentan treatment
[14–17]. In patientswith Down syndrome (DS), the treatment effect of
bosentan is largely unknown [18]. The aimof our studywas to evaluate
the long-termefﬁcacy of bosentan treatment and4 years survival rates
of adult patients with PAH associated with CHD with and without the
DS.
Table 1
Baseline characteristics of the study population.
Patients
without DS
Patients
with DS p-value
(n=34) (n=30)
Age, years 46±14 36±10 0.001
Male gender, (%) 11 (32) 19 (63) 0.01
Eisenmenger syndrome, (%) 27 (79) 30 (100) 0.01
Median follow-up, months (range) 47 (2–64) 48 (13–
60)
0.3
Underlying congenital heart defects
Atrial septal defect primum 2 0
Atrial septal defect secundum (closed) 6 (3) 0
Atrial septal defect sinus venosus 2 0
Atrial septal defect+ventricular septal
defect
2 0
Ventricular septal defect (closed) 8 (2) 7
Ventricular septal defect+patent ductus
arteriosus
2 3
Ventricular septal defect+atresic
pulmonary artery
2 0
Ventricular septal defect+right pulmonary
artery from ascending aorta
1 0
Closed patent ductus arteriosus 1 1
Double inlet left ventricle+patent ductus
arteriosus
2 0
Tetralogy of fallot+Potts anastomosis 1 0
Univentricular heart 3 0
Discordant ventriculo-arterial connection
with ventricular septal defect
2 0
Atrioventricular septal defect 0 18
Atrioventricular septal defect+patent
ductus arteriosus
0 1
NYHA functional class
II 4 8
III 28 20
IV 2 2
Oxygen saturation, (%) 85±8 84±8 0.5
Six-minute walk distance at baseline, m 401±112
Systolic pulmonary arterial pressure, mm Hg 83±23 93±11 0.1
Stroke volume, ml 72±25 67±32 0.6
Cardiac output, L/min 5.3±1.5 4.9±2.2 0.5
NT-pro-BNP, ng/L 1457
±2094
774±956 0.1
Creatinine, μmol/L 80±28 94±30 0.08
Uric acid, mmol/L 0.4±0.1 0.5±01 0.1
Haemoglobin, mmol/L 11±2 13±2 0.001
Mean values with standard deviation. NYHA; New York Heart Association.
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2.1. Study population
Adult patients with Eisenmenger syndrome and the following congenital heart
defects were included: septal defects, patent arterial duct and created aortopulmonary
shunts in cyanotic congenital heart disease (Waterston/Potts shunt). Patients with
persistent PAH after previous closure of their CHD defect were also enrolled. Other
criterion to receive bosentan therapy was proven PAH by right heart catheterisation in
the past with symptoms affecting quality of life (patients in NYHA class 2 to 4). To
exclude other causes of PAH, lung function tests (spirometry, forced expiratory volume
in 1 second, and forced vital capacity) were obtained at baseline. PAH was deﬁned as a
mean pulmonary arterial pressure of more than 25 mm Hg at rest. Patients receiving
prostacyclin, phosphodiesterase type 5 inhibitor, glibenclamide or cyclosporine before
study inclusion and patients with obstruction of the right ventricular outﬂow tract,
pulmonary valve, or pulmonary arteries were excluded. Patients were divided into 2
groups: patients without DS and patients with DS.
2.2. Study design
All patients were evaluated according to a standardized treatment protocol with
clinical examination (determination of functional class) Doppler echocardiography, a
six-minute walk test (6MWT), laboratory tests (including haemoglobin, creatinine, uric
acid, and N-terminal pro-B natriuretic peptide (NT-pro-BNP)) and quality of life
questionnaires These tests (except for echocardiogram) were administered at baseline
and after 3, 6, 9 and 12 months follow-up and from then on twice yearly. All tests were
performed on the same day. Data on events such as death were taken from the
databases of the participating hospitals.
Submaximal exercise capacity was assessed using the 6-MWT, according to the
guidelines of the American Thoracic Society with continuous pulse oximetry
monitoring [19]. To exclude the effect of a learning curve, the 6-MWD at baseline
was performed twice, using the second test as baseline value. In previous research, the
6MWT appeared to be an invalid test to examine exercise capacity in patients with DS
[20]. Therefore in this study 6MWTs were not analyzed to investigate treatment effect
in patients with DS.
Doppler echocardiography (VIVID 7 General Electric, USA) was performed to
evaluate left and right ventricular function during bosentan treatment at baseline and
then yearly. When possible, right ventricular function was measured by tricuspid
annular plane systolic excursion and the systolic pulmonary arterial pressure was
estimated by the peak velocity of the tricuspid regurgitation jet using continuous-wave
Doppler and the pressure off the right atrium, measured by the collapse of the inferior
vena cava. To establish PAH diagnosis, minimal systolic pulmonary arterial pressure
had to be 40 mm Hg at rest with a tricuspid regurgitation velocity of more than 2.8 m/s,
according to the guidelines of the European Society of Cardiology [1]. In patients
without complex cardiac geometry, TEI index and contraction duration of the right
ventricle were assessed using tissue Doppler imaging. Right ventricular contraction
duration, corrected for heart rate, was measured from the onset of the QRS complex to
the onset of early diastolic ﬁlling of the right ventricle (E). Left ventricular stroke
volume was assessed by early systolic measurement of the left ventricular outﬂow tract
diameter (LVOTd), in parasternal long axis view and the velocity time integral (VTI) in
apical long axis view by pulsed wave (PW) Doppler. The PW sample volume was
positioned just proximal the aortic valve leaﬂets, within the left ventricular outﬂow
tract. The VTI was measured by tracing the leading edge of the velocity spectrum.
Stroke volume was calculated according the following formula: Area (A)
=(LVOTd/2)2×π; Stroke volume (SV)=A×VTI. All echocardiographic images were
acquired and recorded digitally, and analyzed ofﬂine by a single observer (RB).
Quality of life was evaluated by means of the SF-36 questionnaire. The SF-36 is a
well-documented, widely used and validated, self-administered quality of life scoring
system incorporating 36 questions. It includes 8 independent scales (scored as a
number between 0 and 100) that assess the following general health concepts: physical
functioning, limitations because of physical health problems (role physical), bodily
pain, general health perceptions, vitality, social functioning, limitations because of
emotional problems (role emotional), and mental health. In patients with DS a close
caretaker or parent was asked to ﬁll out the questionnaire on behalf of the subject.
2.3. Statistical analysis
Descriptive data are presented as mean with standard deviation if normally
distributed or as median with range, as appropriate. Comparisons from baseline to each
consecutive follow-up visit were assessed by paired student t tests. Data for the SF-36
were summarized by mean change from baseline to each time-point for the patients
observed. A value of pb0.05 was considered to be signiﬁcant. As NT-pro-BNP levels
were apparently not normally distributed, statistical analyses were performed on
logarithmically transformed values. Differences of group means and of interval-to-
interval comparisons were analyzed. Logarithmic transformation of the NT-pro-BNP
levels resulted in the bell-shaped distribution. Cox regression analyses was performed
to identify independent predictors for survival (sex, underlying CHD, DS, Eisenmenger
syndrome, age, baseline 6MWD, cardiac output, and NT-pro-BNP). The Wilcoxon
signed-rank test was used to compare the change in NYHA class from baseline to
end-of-study. Death was scored as NYHA class 5. Statistical analysis was performed
with SPSS 16.0.3. Results
3.1. Baseline characteristics
Between January 2005 and July 2010, 70 patients were enrolled in
the treatment protocol. Overall, 64 patients (30 with DS) received
bosentan and were included in this study. Four patients refused
treatment initiation and reimbursement of bosentan by the health
insurance was rejected in 2 patients. The median follow-up duration
was 42 months (range 2 to 64 months). Table 1 summarizes patients'
baseline characteristics. Of the 7 non-DS patients without Eisenmen-
ger syndrome, 6 patients had persistent PAH after previous closure of
their CHD and 1 patient had refused an operation. During follow-up
only 1 patient was treated with concomitant therapy and sildenaﬁl
was started after 2.5 years follow-up on monotherapy with bosentan.
3.2. Survival analysis
In total, 13 people died during 4-years of follow-up, 4 patients with
DS and 9 patients without DS. Table 2 shows detailed information
about the deceased patients. Survival rates in patients without DS at
1-, 2-and 4-years were respectively 88%, 88% and 72%, and for patients
with DS 97%, 93% and 80%. Fig. 1 shows the Kaplan–Meier survival
Table 2
Mortality.
Deceased Male Down
syndrome
NYHA Follow-up Age at death Cause of death Congenital heart defect
(baseline) (months) (years)
Patient 1 0 0 3 2 49 Unknown Double inlet left ventricle+patent arterial duct
Patient 2 1 0 3 4 38 Sudden death Ventricular septal defect
Patient 3 1 0 3 5 44 Sudden death Atrial septal defect+ventricular septal defect
Patient 4 0 0 3 5 76 Right heart failure Atrial septal defect secundum
Patient 5 1 1 2 13 30 Brain abscess Atrioventricular septal defect
Patient 6 0 1 4 20 28 Unknown Atrioventricular septal defect
Patient 7 1 0 3 32 75 Right heart failure Atrial septal defect primum
Patient 8 0 1 3 36 56 Right heart failure Ventricular septal defect
Patient 9 1 0 3 38 26 Sudden death Ventricular septal defect
Patient 10 0 0 3 46 38 Right heart failure Discordant+ventriculo-arterial connection+ventricular septal defect
Patient 11 0 0 3 48 65 Right heart failure Ventricular septal defect
Patient 12 1 1 2 50 34 Right heart failure Atrioventricular septal defect
Patient 13 1 0 4 55 52 Unknown Atrial septal defect secundum
NYHA; New York Heart Association.
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in patients without DS and 4.6±0.2 year in patients with DS. No
signiﬁcant independent predictors for survival were found. Underly-
ing cardiac defect did not inﬂuence survival outcome. Even so,
patients with Eisenmenger syndrome had no better survival com-
pared to patients with persistent PAH after shunt closure (p=0.5).
3.3. Six-minute walk test
Bosentan showed a prolonged signiﬁcant improvement of the
6MWD in the patient group without DS (see Fig. 2). The mean 6MWD
maximally increased with +41 m from 417±108 to 458±104 m
(p=0.002) at 6 months of treatment and remained increased with
+36 m after 2.5 years of follow-up (p=0.003). Afterwards, improve-
ment of 6MWDwas still observed although not statistically signiﬁcant
(p=0.2) in the smaller patient population. Themajority (n=6) of the
9 deceased patients without DS showed initial improvement of
6MWD at 3 months. Two patients had no response and 1 patient died
before ﬁrst follow-up visit at 3 months.
Mean resting heart rate at baseline (85±12 bpm) decreased
signiﬁcantly during follow-up. Mean reduction was 6, 7, 12 and
12 bpm at respectively 1 year (p=0.02), 2 year (p=0.03), 3 year
(p=0.01) and 4 year (p=0.04) follow-up. Themeanmaximumheart
rate during the 6MWT did not change signiﬁcantly during follow-upFig. 1. 4-years survival of all patients. DS; Down syndrome.compared to baseline (111±17 bpm). Mean resting oxygen satura-
tion at baseline was 88% and did not change signiﬁcantly during
4 years follow-up. The mean minimum oxygen saturation during the
6MWT was 71% and no signiﬁcant improvement was found during
follow-up.
3.4. Echocardiography
Echocardiographic parameters at baseline and during treatment
are shown in Table 3. In general, most echocardiographic parameters
remained unchanged in both groups of patients during follow-up.
However, analyses of the left ventricle in patients without DS showed
that mean stroke volume signiﬁcantly increased (+13.5 ml) after
3 years follow-up (p=0.02). Even so, mean cardiac output tended to
increase without reaching signiﬁcance.
3.5. Laboratory testing
Baseline levels of laboratory test are shown in Table 1. The mean
logNT-pro-BNP level decreased signiﬁcantly from 2.8±0.5 to 2.7 m±
0.5 ng/L (p=0.03) at 3 months, at 6 months (p=0.02) and 1 year
(p=0.05) of treatment (see Fig. 3). After 1 year follow-up, logNT-pro-
BNP levels returned to baseline levels and tended to deteriorate
(although not statistically signiﬁcantly). Haemoglobin, creatinine and
uric acid levels did not change signiﬁcantly. No correlation could be
found between baseline 6MWD or change in 6MWD during bosentan
treatment and baseline logNT-pro-BNP. In addition, no relations wereFig. 2. 6MWD in patients without DS during follow-up. DS; Down syndrome.
Table 3
Echocardiography parameters during follow-up.
Non Down syndrome Baseline Δ 1 year FU p-value Δ 2 year FU p-value ΔN3 year FU p-value
Heart rate, bpm 78±11 −0.1 1.0 −3.1 0.3 −5.0 0.1
Stroke volume, ml 72.3±25.9 8.5 0.06 7.8 0.4 13.5 0.02
Cardiac output, L/min 5.5±1.6 0.7 0.2 0.6 0.4 0.6 0.1
TEI index 0.5±0.2 0.03 0.6 0.06 0.6 0.10 0.1
Tricuspid annular plane systolic excursion, cm 1.9±0.6 −0.1 0.9 1.2 0.4 1.0 0.6
Pulmonary arterial pressure, mm Hg 84±23 −3.0 0.6 −6.4 0.2 −4.5 0.3
Down syndrome
Heart rate, bpm 75±12 1.1 0.7 −2.8 0.4 0.9 0.8
Stroke volume, ml 68.9±37.0 5.4 0.2 7.3 0.1 −1.9 0.8
Cardiac output, L/min 5.1±2.5 0.4 0.3 0.2 0.5 −0.1 0.8
TEI index 0.6±0.2 0 0.9 −0.06 0.3 −0.05 0.4
Tricuspid annular plane systolic excursion, cm 1.9±0.4 0.9 0.4 −0.5 0.7 0.6 0.4
Pulmonary arterial pressure, mm Hg 97±16 −7.3 0.05 −5.2 0.2 −3.7 0.4
Mean values with standard deviation. p-values are analyses compared to baseline; FU, follow-up; bpm, beats per minute; FU, follow-up.
TEI index is a combined myocardial performance index (isovolumic contraction time plus isovolumic relaxation time divided by ejection time).
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acid levels.
3.6. Quality of life
Quality of life improved signiﬁcantly in 2 of the 8 scales assessed
by the SF-36, as shown in Fig. 4a and b. Daily life limitations caused by
physical health problems (role physical) improved signiﬁcantly
compared to baseline and the improvement seemed to persist during
longer-term follow-up (Fig. 4a). In addition, physical functioning
improved signiﬁcantly after 3 months and the improvement remained
until 3 years of bosentan treatment (Fig. 4b). In patients with DS, all
8 scales of the SF-36 showed no signiﬁcant improvement of quality of
life.
3.7. NYHA classiﬁcation
NYHA classiﬁcation was assessed at baseline and at the end-of-
study visit. The majority of patients were in NYHA class III at baseline.
NYHA class had improved in 23% of patients, had deteriorated in 25%
of patients and had remained stable in 52% of patients (see Table 4).
NYHA class did not change signiﬁcantly during follow-up (p=0.07).Fig. 3.NT-pro-BNP level in all patients during follow-up. NT-pro-BNP; N-terminal pro-B
natriuretic peptide.Although a trend towards worsening in NYHA class was shown in
patients without DS.
3.8. Safety
Induction of oral bosentan therapy was well tolerated in both
patient groups, without signs of decreasing oxygen saturation. One
patient without DS experienced severe throat pain and dose was
reduced to twice daily 62.5 mg in another patient without DS, who
experienced headaches shortly after bosentan initiation, dose was
ultimately reduced to 32.5 mg twice daily. A third patient without DS
had an asymptomatic increase in liver transaminases (N3 times upper
limit of normal), which resolved within 2 weeks after dose reduction,
whereupon the 125 mg twice daily dose was resumed without
reoccurrence.
4. Discussion
This is the ﬁrst study reporting on the effect of 4 years of bosentan
treatment on exercise capacity, stroke volume and quality of life in
adult patients with PAH associatedwith CHD.We showed a prolonged
increase in exercise capacity after 2.5 years of treatment in patients
without DS. A beneﬁcial effect was still present up to 4 years of
treatment, although failed to reach statistical signiﬁcance due to low
patient numbers. In 2006, the BREATHE-5 study was the ﬁrst
randomised controlled trial which studied the effect of bosentan in
patients with Eisenmenger syndrome. Mean improvement of 6MWD
in 37 patients was+53 m after 4 months of treatment and the overall
improvement was+61 m in 26 patients after 10 months of treatment
in BREATHE-5 combined with the open-label extension study [6,21].
Two longer-term follow-up studies found a signiﬁcant increase and
maintained effect in 6MWD after 1 year and 2 years of bosentan
treatment [9,10]. However, 2 other studies only reported a short term
efﬁcacy of bosentan followed by gradual return to baseline after 2 year
follow-up [14,15]. Duffels et al. hypothesized that this decline in
6-MWD during treatment might be due to the development of
tolerance for bosentan [15]. Our 4 years follow-up study demon-
strates that a prolonged effect of bosentan on exercise capacity can be
expected in patients with PAH due associated with CHD. We believe
clinical stability at 4 year follow-up could be considered successful in
a disease that is associated with clinical deterioration.
Additionally, quality of life improved signiﬁcantly and a remaining
effect was shown after 3 years of treatment in patients without DS.
Although some quality of life domains remained stable during
treatment, others improved signiﬁcantly. The physical domains role
physical and physical functioning increased signiﬁcantly during
bosentan treatment, indicating that patients experienced fewer
Fig. 4. Quality of life scores in patients without DS. Quality of life scores of the 2 SF-36 domains (a) role physical and (b) physical functioning during follow-up. Data represent the
mean score of the SF-36 quality of life questionnaire.
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health related quality of life has been shown to be signiﬁcantly
impaired and evaluation of quality of life is of great importance
[22,23]. Moreover, from the patients' perspective, quality of life is one
of the most important measures of treatment effect.
We evaluated treatment effect in patients with DS as PAH is
particularly common in these patients [24]. In the 2 years follow-up
study of Duffels et al., a change on 6MWD was not found due to the
disputable validity of the 6MWD in patients with DS [15,20]. The
6MWD appeared to be related to the level of intellectual disability
[20]. Therefore, analysis of 6MWD in patients with DS was not
performed in the present study. In patients with DS no signiﬁcant
improvement of quality of life could be demonstrated All 8 domains of
the SF-36 questionnaire remained stable. The SF-36 questionnaire has
not been properly validated in patients with DS making its use for the
evaluation of treatment effect questionable. Moreover, echocardio-
graphic parameters remained unchanged during follow-up. There-
fore, evaluation of treatment effect remains challenging in patients
with DS.
Mean NT-pro-BNP level of the total patient group decreased
signiﬁcantly at 3 months, 6 months and 1 year of follow-up, indicating
a positive cardiac effect and lowered right heart decompensation.
After 1 year, mean NT-pro-BNP levels returned to baseline. Conclu-
sions on long-term treatment effect after 1 year should be taken with
caution due to low patient numbers.
A signiﬁcant change of 13.5 ml in mean stroke volume was found
after 3 years follow-up (p=0.02) in patients without DS. This
corresponds to the recent ﬁndings of vanWolferen et al. who showed
that stroke volume is an important hemodynamic parameter to reﬂect
therapeutic changes during follow-up of PAH [25,26]. In the study of
van Wolferen et al., 111 patients with PAH (90% idiopathic PAH and
PAH associated with connective tissue disease) were evaluated with
cardiac MRI to assess stroke volume at baseline and after 1 year. The
minimal important difference was determined using statistical
methods and a 10 ml change in stroke volume during follow-up wasTable 4
Changes from baseline to end-of-study NYHA class.
Initial minus ﬁnal NYHA class −3 −2 −1 0 1 Total
Non Down syndrome 0 8 1 21 4 34
Down syndrome 2 1 4 12 11 30
NYHA; New York Heart Association Class.
NYHA class did not change signiﬁcantly during follow-up assessed by the Wilcoxon
signed-rank test.considered to be clinical relevant [26]. In this respect, the 13.5 ml
increase of stroke volume we found in our study can be considered of
clinical importance.
Patients with Eisenmenger syndrome are at high risk of death [27]
and despite the widespread use of advanced therapies very little
evidence on survival beneﬁts is currently available. Survival analysis
in the present study showed that after 4 years of follow-up, 20% of the
patients died. Dimopoulos et al. found a much lower mortality rate in
their retrospective study [28]. Only 2 patients died of a total of 68
Eisenmenger patients (including DS) who received advanced therapy
for a median period of 2.4 years (the vast majority of them were in
class III or IV at baseline). Two-years overall survival rate was 91% in
our study. However, 4 patients died within 6 months after baseline
and effect of bosentan might not have been present. Bosentan is not
expected to prevent arrhythmic events but rather progressive
deterioration and right ventricular failure. In patients younger than
50 years, only 2 died of right ventricular failure. The majority of them
died suddenly. Coppus et al. showed that survival of adults with DS is
generally lower compared to the general population due to other
comorbid factors like dementia and impaired mobility [29]. In the
present study, DS was not an independent predictor for survival, most
probably due the relatively young patient population. Themean age of
patients with DS was 10 years lower than patients without DS (36 vs
46 years). Hypothetically, the underlying congenital defect effects
disease progression, however, the post hoc subgroup analysis of the
BREATHE-5 study by Berger et al. showed that effect of bosentan
treatment was similar in Eisenmenger patients with atrial septal
defects and patients with ventricular septal defects [30].
The present study is limited by the lack of a placebo group and the
heterogeneity of underlying diagnoses e.g. patients with and without
the DS, patients with and without Eisenmenger syndrome, patients
with and without closed defects and the variety of defects. Second
limitation is the lacking data on time from PAH diagnosis to study
inclusion. Most patients had PAH many years before study inclusion.
Thirdly, the 6MWT and the SF-36 are not validated in patients with
DS. Therefore, deﬁnite conclusions on long-term treatment effect of
bosentan should be taken with caution in these patients. Another
limitation is that not all echocardiographic measurements could be
performed in patients with complex cardiac geometry and intra- and
inter-observer variability testing was not carried out, however all
echocardiograms and analyzing were performed by 1 single observer.
Finally, the present study was limited by the lack of hemodynamic
data like pulmonary vascular resistance and pulmonary artery
pressure. We may assume that PAH diagnosis was made in the past
in most patients by right heart catheterisation, except probably for
69J.C. Vis et al. / International Journal of Cardiology 164 (2013) 64–69some high risk patients with Eisenmenger syndrome, in whom right
heart catheterisation was not routinely performed as pulmonary
arterial hypertension is clearly evident on echocardiography and
these patients are known to be at high risk for complications due to
this invasive procedure cardiac catheterisation. Due to this compli-
cation risk cardiac catheterisation was not performed to evaluate
treatment effect at follow-up.
In conclusion, we demonstrate a prolonged beneﬁcial effect of
bosentan treatment on exercise capacity, stroke volume and quality of
life in patients without DS. However the mortality rate of 20% of
patients after 4 years of follow-up remains high.
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